Pandemic H1N12009 influenza and HIV: A review of natural history, management and vaccine immunogenicity

Current Opinion in Infectious Diseases

Volumn 25, Issue 1, 2012, Pages 26-35

  Cooper, Curtis L ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

H1N1 influenza; HIV; Neuraminidase inhibitors; Pandemic; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AS 03; IMMUNOSTIMULATING AGENT; INFLUENZA VACCINE; MIFAMURTIDE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADJUVANT THERAPY; ANTIVIRAL THERAPY; CHILL; CLINICAL FEATURE; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EATING HABIT; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFECTION SENSITIVITY; INFLUENZA VACCINATION; INJECTION SITE CONTUSION; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALAISE; MORTALITY; MYALGIA; NAUSEA AND VOMITING; PAIN; PREDICTOR VARIABLE; PROGNOSIS; REVIEW; RHINITIS; RISK; RISK FACTOR; SEROLOGY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE SUSCEPTIBILITY; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS;

EID: 84055192761     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834ef56c     Document Type: Review

References (43)

1. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680-689.
2. Hospitalized patients with novel influenza A (H1N1) virus infection: California, April-May, 2009. Morb Mortal Wkly Rep 2009; 58:536-541.
3. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States April-June 2009. N Engl J Med 2009; 361:1935-1944.
4. Zarychanski R, Stuart TL, Kumar A, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010; 182:257-264.
5. Klein MB, Lu Y, DelBalso L, et al. Influenza virus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007; 45:234-240.
6. Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000; 31:604-606.
7. Cooper C, Thorne A, Klein M, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One 2011; 6:e17758.
8. Evison J, Farese S, Seitz M, et al. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009; 48:1402-1412.
9. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18:3040-3049.
10. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161:441-446.
11. Althoff KN, Eichelberger M, Gange SJ, et al. Sero-incidence of 2009 H1N1 infection in HIV-infected and HIV-uninfected women in the US prior to vaccine availability. AIDS 2011; 25:1229-1232.
12. Kok J, Tudo K, Blyth CC, et al. Pandemic (H1N1) 2009 influenza virus seroconversion rates in HIV-infected individuals. J Acquir Immune Defic Syndr 2010; 56:91-94.
13. Peters PJ, Skarbinski J, Louie JK, et al. HIV-infected hospitalized patients with 2009 pandemic influenza A (pH1N1): United States, spring and summer 2009. Clin Infect Dis 2011; 52 (Suppl 1):S183-S188.
14. Isais F, Lye D, Llorin R, et al. Pandemic (H1N1) 2009 influenza in HIV-infected adults: clinical features, severity, and outcome. J Infect 2010; 61:437-440.
15. Martinez E, Marcos MA, Hoyo-Ulloa I, et al. Influenza A H1N1 in HIV-infected adults. HIV Med 2011; 12:236-245.
16. Ormsby CE, de la Rosa-Zamboni D, Vazquez-Perez J, et al. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS 2010; 25:435-439.
17. Perez CM, Dominguez MI, Ceballos ME, et al. Pandemic influenza A (H1N1) in HIV-1-infected patients. AIDS 2010; 24:2867-2869.
18. Riera M, Payeras A, Marcos MA, et al. Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS 2010; 24:2461-2467.
19. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-2615.
20. Feiterna-Sperling C, Edelmann A, Nickel R, et al. Pandemic influenza A (H1N1) outbreak among 15 school-aged HIV-1-infected children. Clin Infect Dis 2010; 51:e90-e94.
21. Noguera-Julian A, Provens AC, Soler-Palacin P, et al. Pandemic influenza a (2009 H1N1) in human immunodeficiency virus-infected Catalan children. Pediatr Infect Dis J 2011; 30:173-175.
22. Giannattasio A, Lo Vecchio A, Russo MT, et al. Pandemic flu: a comparative evaluation of clinical, laboratory, and radiographic findings in HIV-positive and negative children. AIDS 2010; 24:2292-2294.
23. Labrosse B, Tourdjman M, Porcher R, et al. Detection of extensive crossneutralization between pandemic and seasonal A/H1N1 influenza viruses using a pseudotype neutralization assay. PLoS One 2010; 5:e11036.
24. Bickel M, Wieters I, Khaykin P, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010; 24:F31-F35.
25. Canestri A, Krivine A, Assoumou L, et al. Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients. AIDS 2010; 24:2887-2889.
26. Cooper C, Klein M, Walmsley S, et al. A randomized trial to compare the immunogenicity and efficacy of adjuvanted pandemic H1N1 2009 vaccine with or without booster in HIV+ adults. In Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011.
27. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIVuninfected adults. Clin Infect Dis 2011; 52:138-146.
28. Esposito S, Tagliaferri L, Daleno C, et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 2011; 29:1677-1682.
29. Fabbiani M, Di Giambenedetto S, Sali M, et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 2011; 29:2836-2839.
30. Ho J, Moir S, Wang W, et al. Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS 2011; 25:295-302.
31. Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 2011; 25:177-183.
32. Launay O, Desaint C, Durier C, et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1 v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 2011; 204:124-134.
33. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248-256.
34. Soonawala D, Rimmelzwaan GF, Gelinck LB, et al. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011; 6:e16496.
35. Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24:2187-2192.
36. Yanagisawa N, Maeda K, Ajisawa A, et al. Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. Vaccine 2011; 29:5697-5698.
37. Crum-Cianflone NF, Iverson E, Defang G, et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 2011;29:3183-3191.
38. Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1- infected patients. Vaccine 2011; 29:1359-1363.
39. Calmy A, Bel M, Combescure C, et al. Impact of AS03-adjuvanted pandemic influenza vaccines in HIV-infected and healthy adults. In: 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011); Boston, MA; 2011. p. 440.
40. Pallikkuth S, Pilakka Kanthikeel S, Silva SY, et al. Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J Immunol 2011; 186:6173-6181.
41. Human infection with pandemic (H1N1) 2009 virus. Updated interim WHO guidance on global surveillance. In: Global Alert and Response (GAR) Pandemic (H1N1) 2009 Guidance Documents. World Health Organization; 2009.
42. Kiberd M, Cooper C, Slaunwhite J, et al. Pandemic influenza is a strong motivator for participation in vaccine clinical trials among HIV-positive Canadian adults. Can J Infect Dis Med Microbiol 2009; 20:e124-e129.
43. Cotte L, Voirin N, Richard C, et al. Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients. Vaccine 2011; 29:5638-5644.